Skip Navigation LinksHome > December 15, 2013 - Volume 38 - Issue 26 > Comparison of Deferoxamine and Methylprednisolone: Protectiv...
Spine:
doi: 10.1097/BRS.0000000000000055
Basic Science

Comparison of Deferoxamine and Methylprednisolone: Protective Effect of Pharmacological Agents on Lipid Peroxidation in Spinal Cord Injury in Rats

Dinc, Cem MD*; Iplikcioglu, Ahmet Celal; Atabey, Cem; Eroglu, Ahmet MD; Topuz, Kivanc; Ipcioglu, Osman§; Demirel, Dilaver

Collapse Box

Abstract

Study Design. Experimental study.

Objective. To investigate the protective effect of deferoxamine (DFO) administration in comparison with methylprednisolone (MP) on lipid peroxidation and antioxidants after spinal cord injury (SCI) in rats.

Summary of Background Data. DFO is used for treating an iron-chelating agent, which is also used in the treatment of iron poisoning and thalassaemia. The neuroprotective effect of DFO was evaulated as a therapeutic agent for SCI.

Methods. Forty Wistar rats were randomly divided into 5 groups as sham laminectomy (n = 8), laminectomy with SCI (n = 8), laminectomy with SCI and 0.9% saline intraperitoneal (i.p.) (n = 8), laminectomy with SCI and 30 mg/kg MP i.p. (n = 8), and laminectomy with SCI and 30 mg/kg DFO i.p. (n = 8). Neurological deficits were examined 24 hours after trauma, and all rats were killed. Spinal cord segments were harvested for both biochemical and histopathological evaluation.

Results. At 24 hours post-SCI, whereas malondialdehyde levels were increased, superoxide dismutase, catalase, and glutathione peroxidase levels were decreased in groups I, II, and III. MP and DFO treatment decreased MDA levels and increased superoxide dismutase CAT, and glutathione peroxidase levels in control and study groups. There was no statistically significant difference between treatment with MP and DFO (P> 0.05). All rats were paraplegic after SCI, except in the sham group. Histopathological improvement was observed in control and study groups.

Conclusion. This study indicates that beneficial effects may be provided and further studies need to investigate the dose-dependent beneficial and side effects of DFO in SCI.

Level of Evidence: N/A

© 2013 by Lippincott Williams & Wilkins

Follow Us!

  

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.